Fibrocell Announces One-for-Three Reverse Stock Split
March 10, 2017 09:00 ET
|
Fibrocell Science, Inc.
EXTON, Pa., March 10, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Reports 2016 Financial Results and Recent Operational Highlights
March 09, 2017 08:00 ET
|
Fibrocell Science, Inc.
EXTON, Pa., March 09, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell to Host Conference Call and Webcast on Thursday, March 9, 2017 to Discuss 2016 Financial Results and Recent Operational Highlights
March 07, 2017 17:15 ET
|
Fibrocell Science, Inc.
EXTON, Pa., March 07, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Announces Convertible Preferred Stock Financing for $8.0 Million
March 07, 2017 16:54 ET
|
Fibrocell Science, Inc.
EXTON, Pa., March 07, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Announces Dosing of First Patient in Phase I/II Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa
February 23, 2017 08:00 ET
|
Fibrocell Science, Inc.
EXTON, Pa., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Announces FDA Fast Track Designation of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
January 05, 2017 08:00 ET
|
Fibrocell Science, Inc.
EXTON, Pa., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell Announces Leadership Changes
December 19, 2016 08:00 ET
|
Fibrocell Science, Inc.
John Maslowski Succeeds David Pernock as Chief Executive Officer;Douglas Swirsky Appointed Chairman of the Board of Directors EXTON, Pa., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc....
Fibrocell Appoints Alfred T. Lane, MD, Chief Medical Advisor
November 10, 2016 08:30 ET
|
Fibrocell Science, Inc.
EXTON, Pa., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC) today announced the appointment of Alfred T. Lane, MD, as Chief Medical Advisor of Fibrocell. A board...
Fibrocell Reports Third Quarter 2016 Financial Results and Recent Operational Highlights
November 03, 2016 08:00 ET
|
Fibrocell Science, Inc.
EXTON, Pa., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC) today reported financial results for the third quarter ended September 30, 2016 and recent operational...
Fibrocell to Host Conference Call and Webcast on Thursday, November 3, 2016 to Discuss Third Quarter 2016 Financial Results and Recent Operational Highlights
October 31, 2016 16:01 ET
|
Fibrocell Science, Inc.
EXTON, Pa., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC) will report financial results for the third quarter ended September 30, 2016 and recent operational highlights...